Our platform is based on biocompatible and versatile nanoparticles with specific targeting properties and comprehensive cargo capabilities that allow application to all immune diseases where the antigen(s) are known or can be elucidated. This provides Topas with multiple product opportunities in autoimmune diseases, allergies and in the field of anti-drug antibodies. The clinical validation of our approach is our prime goal at this time. We are pursuing a variety of opportunities both on our own and in collaboration with partners experienced in the respective disease areas.